GlassScriptPhysician profile
James C Tinsley
NPI 1609861038
$1,225.53
in general payments reported to CMS, 2019-2025
16 companies · $163 in 2025
The $163 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $124 · 2021: $212 · 2022: $128 · 2023: $23.51 · 2024: $218 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $404.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.38 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $125.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2024 | Airsupra |
| Axsome Therapeutics, INC. | $120.47 | 2025 | Auvelity |
| Novo Nordisk INC | $114.88 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $111.37 | 2022 | |
| Glaxosmithkline, LLC. | $107.88 | 2020 | |
| Lilly USA, LLC | $85.11 | 2023-2024 | Mounjaro, Reyvow, Emgality |
| Abbvie INC. | $37.43 | 2024-2025 | |
| Ascendis Pharma Endocrinology INC | $26.46 | 2025 | Yorvipath |
| Medicure Pharma INC. | $20.55 | 2021 | |
| Biogen, INC. | $19.27 | 2019 | |
| Boston Scientific Corporation | $18.41 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.53 | 2022 | |
| Bardy Diagnostics, INC. | $15.76 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $10.03 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Tinsley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.